Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4515-4523

  Mroźek, Krzysztof ^a   Marcucci, Guido ^a   Nicolet, Deedra ^a   Maharry, Kati S ^a   Becker, Heiko ^a   Whitman, Susan P ^a   Metzeler, Klaus H ^a   Schwind, Sebastian ^a   Wu, Yue Zhong ^a   Kohlschmidt, Jessica ^a,c   Pettenati, Mark J ^d   Heerema, Nyla A ^b   Block, AnneMarie W ^f   Patil, Shivanand R ^h   Baer, Maria R ⁱ   Kolitz, Jonathan E ^g   Moore, Joseph O ^e   Carroll, Andrew J ^j   Stone, Richard M ^k   Larson, Richard A ^l   Bloomfield, Clara D ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ UNIVERSITY OF MARYLAND   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CEBPA GENE; CHROMOSOME ANALYSIS; COMPUTER SYSTEM; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; FLT3 GENE; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NPM1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; CYTOGENETICS; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871774636     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.4738     Document Type: Article

References (52)

1. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004
2. Smith ML, Hills RK, Grimwade D: Independent prognostic variables in acute myeloid leukaemia. Blood Rev 25:39-51, 2011
3. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008
4. Mrózek K, Marcucci G, Paschka P, et al: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 109:431-448, 2007
5. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
6. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
7. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
8. Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
9. Farag SS, Archer KJ, Mrózek K, et al: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108:63-73, 2006
10. Fröhling S, Schlenk RF, Kayser S, et al: Cytogenetics and age are the main determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 108:3280-3288, 2006
11. Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
12. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
13. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
14. Schlenk RF, Benner A, Krauter J, et al: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 15:3741-3750, 2004
15. Marcucci G, Mrózek K, Ruppert AS, et al: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 23:5705-5717, 2005
16. Mrózek K: Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 35:365-377, 2008
17. Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 61:7233-7239, 2001
18. Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759, 2001
19. Fröhling S, Schlenk RF, Breitruck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380, 2002
20. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
21. Gale RE, Green C, Allen C, et al: The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776-2784, 2008
22. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005
23. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005
24. Thiede C, Koch S, Creutzig E, et al: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011-4020, 2006
25. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010
26. Preudhomme C, Sagot C, Boissel N, et al: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 100:2717-2723, 2002
27. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
28. Bienz M, Ludwig M, Leibundgut EO, et al: Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11:1416-1424, 2005
29. Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. J Clin Oncol 26:5078-5087, 2008
30. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, et al: Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113:3088-3091, 2009
31. Pabst T, Eyholzer M, Fos J, et al: Heterogeneity within AML with CEBPA mutations: Only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 100:1343-1346, 2009
32. Renneville A, Boissel N, Gachard N, et al: The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 113:5090-5093, 2009
33. Röllig C, Bornhäuser M, Thiede C, et al: Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: Evaluation of the proposed reporting system. J Clin Oncol 29:2758-2765, 2011
34. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
35. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
36. Lee EJ, George SL, Caligiuri M, et al: Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B study 9420. J Clin Oncol 17:2831-2839, 1999
37. Baer MR, George SL, Caligiuri MA, et al: Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720. J Clin Oncol 26:4934-4939, 2008
38. Baer MR, George SL, Sanford BL, et al: Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B study 9720. Leukemia 25:800-807, 2011
39. Marcucci G, Moser B, Blum W, et al: A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients > 60 years old. J Clin Oncol 25:360s, 2007 (suppl; abstr 7012)
40. Kolitz JE, George SL, Dodge RK, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B study 9621. J Clin Oncol 22:4290-4301, 2004
41. Kolitz JE, George SL, Marcucci G, et al: P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116:1413-1421, 2010
42. Mitelman F (ed): ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
43. Mrózek K, Carroll AJ, Maharry K, et al: Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience. Int J Oncol 33:239-244, 2008
44. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
45. Westfall PH, Tobias RD, Rom D, et al: Multiple Comparisons and Multiple Tests Using the SAS System. Cary, NC, SAS Institute, 1999
46. Moorman AV, Roman E, Willett EV, et al: Karyotype and age in acute myeloid leukemia: Are they linked? Cancer Genet Cytogenet 126:155-161, 2001
47. Schoch C, Schnittger S, Kern W, et al: Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: Incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. Haematologica 88:351-352, 2003
48. Metzeler KH, Maharry K, Radmacher MD, et al: TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 29:1373-1381, 2011
49. Metzeler KH, Becker H, Maharry K, et al: ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category. Blood 118:6920-6929, 2011
50. Mendler JH, Maharry K, Radmacher MD, et al: RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 30:3109-3118, 2012
51. Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2010
52. Ding L, Ley TJ, Larson DE, et al: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506-510, 2012